CTMX Q2 2020 Earnings — CytomX Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

CTMXCytomX Therapeutics, Inc.

$822M

Q2 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$17M+84.3% YoY

Gross Profit

$17M100.0% margin

Operating Income

-$16M-97.2% margin

Net Income

-$16M-94.4% margin

EPS (Diluted)

$-0.34

QoQ Revenue Growth

-66.5%

Cash Flow

Operating Cash Flow

$97M

Free Cash Flow

$97M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$402M

Total Liabilities

$344M

Stockholders' Equity

$59M

Cash & Equivalents

$291M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$17M	$9M	+84.3%
Gross Profit	$17M	$9M	+84.3%
Operating Income	-$16M	-$31M	+48.3%
Net Income	-$16M	-$29M	+45.9%